ACRS
Aclaris Therapeutics Inc
4.40$
-0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +89.3% | -86.4% | +15.3% | +57.1% | +111.9% | -84.2% | +22.1% | +85.6% | -60.7% | +54.1% | -18.4% | – | |
| – | -21.5% | -71.4% | +3.8% | +26.1% | +286.3% | -94.6% | +265.6% | -70.9% | -249.3% | – | -41.5% | – | |
| – | +922.2% | -95.0% | +53.6% | +126.1% | -104.6% | – | -107.7% | – | -24.0% | -23.7% | -12.7% | – | |
| – | +11.6% | -63.1% | -11.0% | -32.0% | +51.5% | +28.3% | -1.2% | +13.8% | +27.3% | -5.6% | +20.4% | – | |
| – | +20.8% | -16.7% | -30.6% | +19.0% | -12.4% | +23.9% | -12.3% | -9.6% | +14.5% | +20.9% | -10.3% | – | |
| – | -53.5% | +28.3% | -29.6% | -9.5% | +702.5% | -80.9% | -3.7% | +8.6% | +24.7% | -4.2% | +7.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.